Mark Alvino Sells 7,084 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEOGet Free Report) Director Mark Alvino sold 7,084 shares of the stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $5.11, for a total value of $36,199.24. Following the sale, the director now directly owns 62,816 shares in the company, valued at $320,989.76. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Abeona Therapeutics Stock Down 4.1 %

NASDAQ:ABEO opened at $4.87 on Wednesday. The stock’s 50-day simple moving average is $4.89 and its 200 day simple moving average is $4.24. Abeona Therapeutics Inc has a twelve month low of $2.19 and a twelve month high of $5.94.

Abeona Therapeutics (NASDAQ:ABEOGet Free Report) last announced its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.05. As a group, sell-side analysts predict that Abeona Therapeutics Inc will post -2.04 EPS for the current year.

Institutional Trading of Abeona Therapeutics

Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at about $43,000. GSA Capital Partners LLP acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at about $49,000. Bank of New York Mellon Corp acquired a new stake in shares of Abeona Therapeutics during the second quarter valued at about $52,000. Creative Planning acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at about $59,000. Finally, Simplex Trading LLC boosted its stake in shares of Abeona Therapeutics by 1,889.9% during the third quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 13,418 shares in the last quarter. 43.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, January 15th.

Read Our Latest Analysis on Abeona Therapeutics

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.